Zydus Lifesciences Limited Announces Loss of Share Certificate
Zydus Lifesciences Limited published a notice about a lost share certificate for Mr. MUld Narayana. The certificate covers 1500 shares. A duplicate will be issued if no objections are raised within seven days of the September 24, 2026 publication.
The loss of a single share certificate is a common occurrence and typically has a minimal impact on the overall operations and market valuation of a large listed company like Zydus Lifesciences Limited.
The announcement is a routine regulatory filing regarding a lost share certificate and does not inherently carry positive or negative implications for the company's financial performance or business operations.
Zydus Lifesciences Limited has published a notice regarding the loss of a share certificate. The company received an intimation from a shareholder, Mr. MUld Narayana, stating that the share certificate pertaining to equity shares held by him has been lost or misplaced.
The details provided for the lost certificate are: Folio Number 1442ll6-015290, 1500 shares, Distinctive Numbers 1259 to 1443805.
The notice, published in the Financial Express (English and Gujarati editions) on September 24, 2026, states that if no objection is received within seven days from the publication date, the company will proceed to issue a duplicate share certificate to the shareholder. The public is cautioned against dealing with the mentioned share certificate, as the company will not be responsible for any resulting loss or damage.
This notice was issued by Dhaval N. Soni, Company Secretary & Compliance Officer of Zydus Lifesciences Limited, on September 23, 2026, from Ahmedabad.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under loss of share certificate. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.